Background Lumefantrine and mefloquine are used worldwide in artemisinin-based
combination therapy (ACT) of malaria. Better understanding of drug susceptibility and …

Malaria control is compromised by the development and spread of Plasmodium falciparum
resistance to antimalarial drugs, which has caused an increase in malaria related morbidity …

Background Artemether-lumefantrine (AL) is a major and highly effective artemisinin-based
combination therapy that is becoming increasingly important as a new first-line therapy …

Background Artemisinin-based combination therapy (ACT) partner drugs, currently used in
Ghana are lumefantrine, amodiaquine and piperaquine. Plasmodium falciparum isolates …

Background: Artemether-lumefantrine is a highly effective artemisinin-based combination
therapy that was adopted in Mali as first-line treatment for uncomplicated Plasmodium …

Background Individual drug treatment may select resistant parasites in the human body, a
process termed in vivo selection. Some single nucleotide polymorphisms in Plasmodium …

Background The use of artemisinin as a monotherapy resulted in the emergence of
artemisinin resistance in 2005 in Southeast Asia. Monitoring of artemisinin combination …

The mechanisms of drug resistance development in the Plasmodium falciparum parasite to
lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We …

In Uganda, artemether-lumefantrine was introduced as an artemisinin-based combination
therapy (ACT) for malaria in 2006. We have previously reported a moderate decrease in ex …

Background Artemisinin-based combination therapy is the first-line anti-malarial treatment
for uncomplicated Plasmodium falciparum infection in Angola. To date, the prevalence of …